5.97 USD
▼-0.23-3.71%
盘后 7.30 0.00%
2026-09-15
市值
$590.14M
市盈率
—
EPS
-0.50
股息率
—
52 周区间
1.70 – 8.33
成交量
895.23K
Beta
1.10
目标价
14.67
52W 低 1.7052W 高 8.33
价格走势
公司简介
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical...